ATE469919T1 - Cd55-interaktionspartner und dessen anwendung - Google Patents

Cd55-interaktionspartner und dessen anwendung

Info

Publication number
ATE469919T1
ATE469919T1 AT03778533T AT03778533T ATE469919T1 AT E469919 T1 ATE469919 T1 AT E469919T1 AT 03778533 T AT03778533 T AT 03778533T AT 03778533 T AT03778533 T AT 03778533T AT E469919 T1 ATE469919 T1 AT E469919T1
Authority
AT
Austria
Prior art keywords
application
interaction partners
scr2
scr1
binds
Prior art date
Application number
AT03778533T
Other languages
English (en)
Inventor
Gillian Lindy Durrant
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE469919T1 publication Critical patent/ATE469919T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03778533T 2002-11-27 2003-11-26 Cd55-interaktionspartner und dessen anwendung ATE469919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0227644.2A GB0227644D0 (en) 2002-11-27 2002-11-27 Specific binding members and uses thereof
PCT/GB2003/005163 WO2004048413A2 (en) 2002-11-27 2003-11-26 Cd55-interaction partners and the uses thereof

Publications (1)

Publication Number Publication Date
ATE469919T1 true ATE469919T1 (de) 2010-06-15

Family

ID=9948597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778533T ATE469919T1 (de) 2002-11-27 2003-11-26 Cd55-interaktionspartner und dessen anwendung

Country Status (14)

Country Link
US (3) US20060134110A1 (de)
EP (1) EP1565494B1 (de)
JP (1) JP5514388B2 (de)
CN (1) CN1826357A (de)
AT (1) ATE469919T1 (de)
AU (1) AU2003285536A1 (de)
BR (1) BR0316741A (de)
CA (1) CA2507106A1 (de)
DE (1) DE60332864D1 (de)
ES (1) ES2345981T3 (de)
GB (1) GB0227644D0 (de)
HK (1) HK1074207A1 (de)
MX (1) MXPA05005725A (de)
WO (1) WO2004048413A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP3431503A1 (de) 2005-01-12 2019-01-23 Proteonova, Inc. Verfahren zur herstellung zielgerichteter therapeutika
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
WO2007033167A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Compositions and methods for detecting and treating cancer
JP2010517583A (ja) 2007-02-12 2010-05-27 プロテオノヴァ、 インコーポレイテッド ｍＲＮＡに連結された可溶性ランダムポリペプチドのライブラリーの生成
WO2019040513A1 (en) * 2017-08-22 2019-02-28 Agonox, Inc. METHODS AND COMPOSITIONS RELATED TO CD55 BINDING AGENT
CN113660945A (zh) * 2019-02-20 2021-11-16 艾根奥克思公司 抗cd55抗体和相关组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
JP2634218B2 (ja) * 1987-03-02 1997-07-23 森永乳業株式会社 Ａｄｃｃ療法を高める組成物
DE69735424T2 (de) * 1996-08-09 2006-10-12 Stichting Sanquin Bloedvoorziening Verfahren und mittel zur modifikation der komplementaktivierungskaskade
GB9804065D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Tumour associated antigen 791Tgp72
DE19909771A1 (de) * 1998-12-22 2000-06-29 Heinz Peter Vollmers Substanz zur Gewinnung hochwirksamer Tumorarzneien sowie Verfahren
CA2356189C (en) * 1998-12-22 2010-08-24 Heinz Peter Vollmers Substance for obtaining highly effective tumor medications as well as a process
JP2002543044A (ja) * 1999-03-01 2002-12-17 ジェネンテック・インコーポレーテッド 癌の治療及び診断のための抗体
GB0111628D0 (en) * 2001-05-11 2001-07-04 Scancell Ltd Binding member

Also Published As

Publication number Publication date
JP5514388B2 (ja) 2014-06-04
BR0316741A (pt) 2005-10-18
JP2006520742A (ja) 2006-09-14
MXPA05005725A (es) 2006-02-10
ES2345981T3 (es) 2010-10-07
WO2004048413A2 (en) 2004-06-10
CA2507106A1 (en) 2004-06-10
DE60332864D1 (de) 2010-07-15
US20170121418A1 (en) 2017-05-04
US20060134110A1 (en) 2006-06-22
US9580512B2 (en) 2017-02-28
US20100136013A1 (en) 2010-06-03
EP1565494B1 (de) 2010-06-02
AU2003285536A1 (en) 2004-06-18
EP1565494A2 (de) 2005-08-24
WO2004048413A3 (en) 2004-07-29
CN1826357A (zh) 2006-08-30
GB0227644D0 (en) 2003-01-08
HK1074207A1 (en) 2005-11-04

Similar Documents

Publication Publication Date Title
EP2266624A3 (de) Duramycin-peptid mit bindung an anionische Phospholipide und Aminophospholipide Konjugate und ihre Verwendung bei der Behandlung von Virusinfektionen
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
DE60333121D1 (de) Pers 14.18, der gd2 bindet und seine fusion mit il-2
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
SG157951A1 (en) Cripto blocking antibodies and uses thereof
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
IL184617A0 (en) Dr5 antibodies and uses thereof
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
BR0311627A (pt) Conjugados covalentes entre endoperóxidos artemisinino-relacionados e proteìnas portadoras de ferro e métodos de utilização
HK1074207A1 (en) Cd55-interaction partners and the uses thereof cd55
ATE366121T1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
GB0111628D0 (en) Binding member
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
MX2007000263A (es) Tratamiento de cancer.
TNSN06454A1 (en) Treatment of cancer
TW200635953A (en) Specific binding agents of human angiopoietin-2
TW200640948A (en) DR5 antibodies and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties